Glimepiride/metformin - Sanofi
Alternative Names: Amaryl M; Amaryl M S.R.; Metformin/glimepiride; SolosametLatest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Sanofi
- Developer Handok Inc; Sanofi
- Class Antihyperglycaemics; Biguanides; Small molecules; Sulfones; Sulfonylureas
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Glucose modulators; Insulinotropin agonists; Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 05 Jul 2019 Chemical structure information added
- 01 Apr 2014 Sanofi completes the phase III LEGEND trial in Type 2 diabetes mellitus in Lebanon, Russia and Ukraine (NCT01699932)
- 03 Oct 2013 Launched for Type-2 diabetes mellitus in South Korea (PO) some time prior to October 2013